Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis : a multicentre, open-label, partially randomised, phase 2b trial
Loading...
Date
Authors
Tweed, Connor D.
Dawson, Rodney
Burger, Divan Aristo
Conradie, Almari
Crook, Angela M.
Mendel, Carl M.
Conradie, Francesca
Diacon, Andreas H.
Ntinginya, Nyanda E.
Everitt, Daniel E.
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Please read abstract in the article.
Description
Keywords
Tuberculosis (TB), Bactericidal activity, Safety profile, Pyrazinamide, Bedaquiline (BDQ), Pretomanid (PA‐824), Moxifloxacin, Pulmonary tuberculosis
Sustainable Development Goals
Citation
Tweed, C.D., Dawson, R., Burger, D.A. et al. 2019, 'Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial', Lancet Respiratory Medicine, vol. 7, no. 12, pp. 1048-1058.